Abstract: Objective To investigate the clinical efficacy and safety of 308 nm excimer laser combined with Tuibai Decoction in the treatment of vitiligo. Methods Total 112 patients with vitiligo admitted to Danzhou People's Hospital from January 2017 to December 2018 were randomly divided into control group(n=56) and observation group(n=56). The control group was treated with 308 nm excimer laser, while the observation group was treated with Tuibai Decoction on the basis of the control group. The clinical efficacy of the two groups after treatment was compared. The skin pigmentation score, skin disease quality of life index(DLQI) score, peripheral blood T lymphocyte subsets, serum interleukin-2(IL-2), interleukin-6(IL-6) and tumor necrosis factor-alpha(TNF-alpha) levels were observed before and after treatment in the two groups. Results The total effective rate of the observation group after treatment was significantly higher than that of the control group(78.57% vs. 60.71%, P<0.05). After treatment, the skin pigmentation scores of the two groups were significantly higher than those of the same group before treatment, and the skin pigmentation scores of the observation group were significantly higher than that of the control group(all P<0.05). After treatment, the DLQI scores of the two groups were significantly lower than those of the same group before treatment, and the DLQI scores of the observation group were significantly lower than those of the control group(all P<0.05). The levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in the two groups after treatment were significantly higher than those before treatment in the same group, and the levels of CD3⁺, CD4⁺ and CD4⁺/CD8⁺ in the observation group were significantly higher than those in the control group after treatment(all P<0.05). Conclusion Excimer laser(308 nm) combined with Tuibai Decoction has better curative effect on vitiligo, which can significantly inhibit the level of inflammatory factors, improve the life quality and immune function of patients, and has better safety.